Summit Global Investments Boosts Stock Holdings in Health Catalyst, Inc. (NASDAQ:HCAT)

Summit Global Investments increased its position in Health Catalyst, Inc. (NASDAQ:HCAT) by 329.2% in the fourth quarter, Holdings Channel.com reports. The fund owned 75,072 shares of the company’s stock after purchasing an additional 57,581 shares during the period. Summit Global Investments’ holdings in Health Catalyst were worth $695,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in the business. Los Angeles Capital Management LLC bought a new stake in shares of Health Catalyst in the fourth quarter worth approximately $108,000. Stratos Wealth Partners LTD. bought a new stake in Health Catalyst in the 3rd quarter worth approximately $114,000. MQS Management LLC bought a new stake in Health Catalyst in the 3rd quarter worth approximately $116,000. Versor Investments LP purchased a new stake in Health Catalyst during the 3rd quarter valued at $117,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of Health Catalyst by 23.0% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 15,072 shares of the company’s stock valued at $140,000 after buying an additional 2,817 shares during the period. 85.00% of the stock is currently owned by hedge funds and other institutional investors.

Health Catalyst Price Performance

HCAT opened at $6.48 on Friday. The company has a 50 day simple moving average of $7.13 and a two-hundred day simple moving average of $8.18. The company has a current ratio of 4.42, a quick ratio of 4.42 and a debt-to-equity ratio of 0.62. Health Catalyst, Inc. has a 1-year low of $5.45 and a 1-year high of $14.37.

Health Catalyst (NASDAQ:HCAT) last issued its earnings results on Thursday, February 22nd. The company reported ($0.21) earnings per share for the quarter, topping the consensus estimate of ($0.27) by $0.06. Health Catalyst had a negative net margin of 39.92% and a negative return on equity of 12.19%. The company had revenue of $75.08 million during the quarter, compared to the consensus estimate of $73.67 million. As a group, equities analysts anticipate that Health Catalyst, Inc. will post -0.47 earnings per share for the current year.

Wall Street Analyst Weigh In

Several analysts recently commented on the company. Canaccord Genuity Group cut their price objective on Health Catalyst from $12.00 to $11.00 and set a “buy” rating for the company in a report on Friday, February 23rd. Piper Sandler restated an “overweight” rating and set a $15.00 price target (down from $17.00) on shares of Health Catalyst in a research note on Friday, February 23rd. Evercore ISI dropped their price objective on shares of Health Catalyst from $11.00 to $10.00 and set an “outperform” rating on the stock in a report on Friday, February 23rd. KeyCorp reaffirmed a “sector weight” rating on shares of Health Catalyst in a report on Wednesday, April 10th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $16.00 price target on shares of Health Catalyst in a research note on Wednesday, April 10th. Four equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $12.10.

Health Catalyst Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.